PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma

PVR/TIGIT and PD-L1/PD-1 axes play essential roles in tumor immune evasion and could be potential targets for combined immunotherapy. We aimed to evaluate the expression status of the above-mentioned immune markers in lung squamous cell carcinoma (LUSC), and investigate their survival impact and rel...

Full description

Bibliographic Details
Main Authors: Zhenlin Yang, Yue Peng, Jiachen Xu, Ping Chen, Zhenshan Zhao, Qingyuan Cai, Lin Li, He Tian, Guangyu Bai, Lei Liu, Shugeng Gao, Jie He
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:Translational Oncology
Subjects:
Lung squamous cell carcinoma
PVR
PD-L1
Prognosis
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523322001607

Internet

http://www.sciencedirect.com/science/article/pii/S1936523322001607

Similar Items